生物制药公司Upstream Bio于2026年美国过敏、哮喘与免疫学会（AAAAI）年会上，正式发布了其核心候选药物Verekitug在慢性鼻窦炎伴鼻息肉（CRSwNP）患者中开展的2期Vibrant临床试验的补充分析数据。此次公布的分析结果进一步揭示了Verekitug在这一适应症中的治疗潜力与作用机制，为后续临床开发提供了重要依据。
生物制药公司Upstream Bio于2026年美国过敏、哮喘与免疫学会（AAAAI）年会上，正式发布了其核心候选药物Verekitug在慢性鼻窦炎伴鼻息肉（CRSwNP）患者中开展的2期Vibrant临床试验的补充分析数据。此次公布的分析结果进一步揭示了Verekitug在这一适应症中的治疗潜力与作用机制，为后续临床开发提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.